- Nirvana Life Sciences Inc. (NIRV) has released dat from its study for the effects of psilocybin on people struggling with heroin addiction
- The company’s project focused on how psilocybin modifies heroin molecular pathways in in vitro rat brain cell line model
- The GeneChip™ Rat Genome 230 2.0 Assay was used to evaluate cells that were treated with heroin and psilocybin separately, and combined
- Nirvana believes the new data can be extremely useful for determining a better understanding of dependent doses
- Nirvana Life Sciences Inc. (NIRV) is up 5.15 per cent trading at $0.51 per share as of 2:07 p.m. ET
Nirvana Life Sciences (NIRV) has released data from its study for the effects of psilocybin on people struggling with heroin addiction.
The company’s project focused on how psilocybin modifies heroin molecular pathways in in vitro rat brain cell line model. It also evaluated the effect of psilocybin on heroin in-vivo self-administration and how reinstatement of heroin following memory retrieval test.
Part of the analysis was performed by the Clariom S Assay tool. This machine serves as a gene profiling tool. Based on microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software.
The GeneChip™ Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cells that were treated with heroin and psilocybin separately, and with the two combined.
The study proved how Nirvana’s technology can aid with heroin relapse prevention which is new to the field of pharmaceutical addictions medicine and chemotherapy.
An analysis for heroin and psilocybin and their co-combination was never investigated prior to this study. Nirvana believes the new data can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin addiction and dependence.
Nirvana Life Sciences Inc. (NIRV) is up 5.15 per cent trading at $0.51 per share as of 2:07 p.m. ET.
